Elanco Animal 医疗 ELAN

Mr. Jeffrey N. Simmons President and Chief Executive Officer, Elanco Animal Health Incorporated (since 2018). Eli Lilly and Company, a global pharmaceutical company (1989 - 2018) - Senior Vice President and President of the Elanco Animal Health division at Eli Lilly (2008 - 2018) ; Held various leadership roles in the Elanco Animal Health division, including International Marketing Manager, Country Director for Brazil, Area Director for Western Europe and Executive Director for U.S. and Global Research & Development. Business Leadership and Operations expertise exhibited as a proven, purpose-driven leader during his 30-plus years in the life sciences industry, including as the head of Elanco for the past decade, during which he directed Elanco's growth and transformation from a primarily U.S. livestock feed additive company to a global animal health leader with a diversified business, more than quadrupled revenue, created a unique innovation engine and built five new businesses, including a greater than $2 billion pet health business. M&A and Business Development experience acquired while evaluating, executing and integrating several significant acquisitions during his tenure as Elanco's CEO, including the acquisitions of Aratana Therapeutics, Kindred Biosciences and Bayer Animal Health, one of the largest animal health transactions to date. Risk Management and Sustainability expertise shown as Elanco has demonstrated its commitment to sustainability, including through its commercialization and advancement of Bovaer, Elanco's methane reduction product, and its development of a carbon insetting marketplace. Research and Development/Innovation experience acquired through his oversight of research and development programs over the past three decades, including the successful product launch of numerous animal health blockbuster drugs while serving as Executive Director for U.S. and Global Research & Development as well as other senior leadership roles within the Elanco Animal Health Division of Lilly

Mr. Robert M. VanHimbergen serves as our Executive Vice President and Chief Financial Officer, a position he has held since he joined Elanco in July 2025. Mr. VanHimbergen oversees our financial operations, including our treasury, investor relations, tax functions, and commercial finance teams as well as information technology and procurement. He brings significant financial leadership and enterprise transformation experience. Prior to joining Elanco, Mr. VanHimbergen served as Senior Vice President and Chief Financial Officer of Hillenbrand, Inc., a global industrial company, from April 2022 to June 2025. Prior to joining Hillenbrand, he spent 15 years at Johnson Controls, a global leader in smart, healthy, and sustainable buildings, where he led the global finance, accounting and reporting functions, was a member of the executive leadership team and was deeply involved in Johnson Controls' enterprise transformation initiative. Mr. VanHimbergen held other roles within Johnson Controls, including CFO of a $9 billion automotive interiors business in Shanghai, China, and led the battery division in Asia. Prior to Johnson Controls, Mr. VanHimbergen spent nearly a decade at PricewaterhouseCoopers LLP working with large multi-national companies. Mr. VanHimbergen received his bachelor's degree in accounting from St. Norbert College.

Ms. Ellen de Brabander, PhD serves as our Executive Vice President, Innovation and Regulatory Affairs. Dr. de Brabander joined Elanco in October 2021 and is responsible for our global research and development, external innovation and regulatory affairs organizations and as such is responsible for progressing and refilling the innovation pipeline. She is a highly experienced research and development executive with a proven track record of accomplishments in animal health, life sciences and fast-moving consumer goods sectors. From March 2014 to October 2021, Dr. de Brabander served as senior vice president for research and development with PepsiCo, a global food and beverage company, most recently having company-wide responsibility for food safety, quality, regulatory and research and development digital transformation. Prior to PepsiCo, she led research and development organizations for Merial (now Boehringer Ingelheim Animal Health), Intervet (now Merck Animal Health) and DSM. Dr. de Brabander currently serves on the boards of the Archer-Daniels-Midland Company, Brightlands Campus Greenport Venlo B.V., and LTS Lohmann Therapie-Systeme AG. Dr. de Brabander earned her doctorate (cum laude) in bio-organic chemistry from Leiden University in the Netherlands and completed her post-doctoral work in molecular biology at the Massachusetts Institute of Technology. She has lived in six different countries, is the co-author of more than 60 publications in scientific journals, holds 18 patents and has received multiple awards for her research, including the Golden Medal from the Royal Dutch Chemical Society in 2000 for Best Chemist Under 40.

Mr. Timothy J. Bettington serves as our Executive Vice President, Center of Strategic Growth. With more than 25 years in the animal health industry, Mr. Bettington joined Elanco in 2023, after serving as EVP and President of U.S. Operations and Global Customer Experience at Zoetis, an animal health company, from January 2020 to November 2022. At Zoetis, he led U.S. Commercial operations, supporting the livestock and companion animal portfolios. Prior to that, Mr. Bettington served in roles with increasing responsibility over the course of his career, including as Global Head Commercial Excellence from 2015 to 2016 and North American Region Head of Commercial Operations from 2017 to 2019, both at Boehringer Ingelheim Animal Health, an animal health company, working both in the livestock and companion animal sectors. Mr. Bettington has worked in the U.S., Europe and Australia and has developed a deep expertise in sales excellence, marketing, strategy, and business integration. Mr. Bettington holds a bachelor's degree in Agriculture from Western Sydney University and a master's degree in Marketing Management from the Macquarie Graduate School of Management in Sydney, Australia.

Mr. Lawrence E. Kurzius McCormick & Company, Inc., a global Fortune 500 food company (since 2005) - Executive Chairman (since 2023). Chairman and Chief Executive Officer (2017 - 2023); Chief Executive Officer (2016); Held various leadership roles, including President and Chief Operating Officer; Chief Administrative Officer; President, International Businesses; President, Europe, Middle East and Africa; President, U.S. Consumer Foods. Zatarain's, an American food company - President and CEO (1997 - 2004 when acquired by McCormick); Vice President and Marketing Director (1991 - 1997). Marketing executive, Quaker Oats Company and Mars Inc.'s Uncle Ben's Company. Other Current Public Company Boards: The Cooper Companies, Inc. (since 2023). McCormick & Company, Inc. (since 2015), Executive Chairman (since 2023), Chairman (2017 - 2023). experience acquired over his career in consumer goods marketing and senior leadership roles at Mars, Quaker Oats, Zatarain's and McCormick, a large, multi-faceted, consumer and flavor solutions food business, and further developed while serving on the boards of multiple industry groups, including The Consumer Goods Forum, The Consumer Brands Association and The National Association of Manufacturers, resulting in his extensive knowledge of consumer trends and a deep understanding of consumer preferences. Global Business Experience gained leading multinational companies, where understanding both the domestic and international markets was essential to success. Human Capital Management expertise developed through his leadership of a company with over 14,000 employees globally, which has resulted in a deep understanding of attracting, developing, motivating and retaining top talent, as well as executive compensation and leadership development. Risk Management and Sustainability experience obtained from his broad executive experience at McCormick, where under his leadership, the company became a UN Global Compact LEAD company while embedding purpose-led performance into McCormick's culture by championing the company's industry-leading sustainability efforts.

Mr. Kirk McDonald Founding member and Chief Executive Officer at Sundial Media Group, a virtually integrated media, technology and experiential company (since 2024); Chief Executive Officer and member of Global Leadership Team, GroupM North America, a global provider of media and advertising solutions through the development of technology-enabled services (2020 - 2023); Chief Business Officer, AT&T's advertising division, Xandr (September 2019 - August 2020); Chief Marketing Officer (November 2018 - September 2019); Leadership roles at several other leading companies, including President, PubMatic; President of Digital, Time Inc.; Chief Advertising Officer, Fortune/Money Group; Senior Vice President of Network Sales, DRIVEpm and Atlas (both units of Microsoft's advertising business). Other Current Public Company Boards: Ziff Davis, Inc. (since 2023). Business Leadership and Operations expertise gained over his significant career in leadership roles with responsibility for developing and executing on business strategies. Consumer Products experience gained during his more than 30 years of experience in marketing leadership roles at leading companies like Microsoft and AT&T. Digital, Technology and Cybersecurity expertise developed at GroupM, where he helped develop technology-enabled services for media and advertising solutions, resulting in experience with digital and emerging technologies; recognized by AdWeek for his digital expertise as one of the 50 vital leaders in tech, media and marketing. Human Capital Management insights gained as Chief Executive Officer of GroupM, an organization of approximately 6,500 people in a fast-growing industry

Mr. Art A. Garcia CPA, Served in various leadership roles at Ryder System, Inc., primarily a North American provider of transportation and supply chain management products known for its fleet of rental trucks, including as its Executive Vice President and Chief Financial Officer (2010 - April 2019); Senior Vice President and Controller (2005 - 2010); Vice President and Controller (2002 - 2005); Other Current Public Company Boards: Raymond James & Associates (director-elect April 2023); American Electric Power Company, Inc. (2019 - present); ABM Industries Incorporated (since 2017). Business Leadership and Operations expertise acquired through his experience leading the finance organization at Ryder Systems, where he led the re-engineering of the organization to help drive efficiency, established a new business model and implemented strategies to revitalize growth and improve profitability. Finance and Accounting experience developed during the 18 years he served in financial roles at Ryder Systems, where he ultimately had oversight of the entire financial function for almost a decade and during his service on the audit, risk management and governance committees on the boards of other public companies. M&A and Business Development expertise obtained while overseeing the corporate strategy and business development functions and managing the financial integration of numerous acquisitions at Ryder Systems. Institutional Investor Perspective developed through his nearly 10 years of experience engaging with the financial community as a public company Chief Financial Officer

Dr. Denise Vera Scots-Knight, PhD, Co-Founder, Chief Executive Officer and Director, Mereo BioPharma Group plc, an international biopharmaceutical company focused on oncology and rare diseases (since 2015). Partner, Phase4 Ventures GP Ltd., Phase4 Ventures GP III Ltd., Phase4 Ventures III FPGP Ltd., Phase4 Ventures III GP LP, and Phase4 Ventures III FP LP, privately held global life science venture capital firms (2010 - 2019). Chief Executive Officer, Phase4 Partners Ltd., a privately held, global life science venture capital firm (2010 - 2015). Head, Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution (2004 - 2010). Other Current Public Company Boards: Mereo BioPharma Group plc (since 2015). OncoMed Pharmaceuticals Inc. (2008 - 2018). Albireo Pharma, Inc. (2008 - 2017). Health Care Industry experience acquired over her career in the life sciences industry, and through her current and past service as a director of other public and privately held biotech and life sciences companies and supported by being named of one of the 15 leading women in European biotech by Labiotech UG. Global Business Experience gained through her service as Co-Founder and Chief Executive Officer of Mereo BioPharma, a United Kingdom-based, Nasdaqlisted company with operations in the U.S., as well as leadership roles in other nonU.S. organizations, which further developed her valuable insights into global strategic oversight, talent and leadership development that are critical in our growth-oriented industry. Institutional Investor Perspective obtained through her extensive experience investing and allocating capital as the head of a life sciences-focused venture capital firm. Research and Development/Innovation expertise developed through her career, where she has a track record of building new innovation models and strategic partnerships for emerging technologies, which has resulted in her having a deep acumen and technical expertise beneficial for overseeing our research and development activities.

Ms. Kapila Kapur Anand, CPA, KPMG LLP, one of the world's leading accounting firms - Senior Advisor (2016 - 2020); -Audit Signing Partner and Advisory Partner (1989 - 2016); -Elected to KPMG's U.S. and Americas boards (2005 - 2010) and Chair of the KPMG Foundation. Other Current and Prior Public Company Boards: Omega Healthcare Investors Inc. (since 2018); Extended Stay America, Inc. and its REIT subsidiary, ESH Hospitality, Inc. (2016 - 2021). experience gained through her more than 30 years of services as a Certified Public Accountant at KPMG and utilized during her service on the audit committees of multiple public companies expertise developed over her career advising companies throughout their life cycle on topics such as strategic planning, due diligence, risk assessments, enterprise risk management, and setting up proper internal controls and further honed through her work as an advisory partner to KPMG's risk and governance practice. experience acquired while playing a leading role in the development of KPMG's private equity and regulatory businesses. experience obtained while acting as an advisory partner to KPMG's M&A and integration services practices.

Dr. Stacey Ma, PhD, Executive Vice President of Pharmaceutical Development and Manufacturing, Gilead Sciences, Inc., a research-based biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines (since 2022); Executive Vice President of Technical Operations, Sana Biotechnology, a biotechnology company focused on utilizing engineered cells as medicines (2019-2022); Genentech, Inc., an American biotechnology company and member of the Roche Group (1996 - 2019): Global Head of Innovation, Manufacturing Science and Technology (2018 - 2019); Roles of increasing responsibility, including Vice President, Global Head of IMP Quality, Pharma Technical Development. Prior Public Company Boards: Atreca, Inc. (2021-2024). Animal Health/Health Care Industry experience gained through nearly 30 years of experience in the health care industry, including with Gilead Sciences, Inc., Sana Biotechnology, and Genentech, Inc. Business Leadership and Operations leader with extensive experience in product and supply chain management, manufacturing, and quality operations. Research and Development/Innovation expertise developed by leading technology innovation and product development at leading human pharmaceutical companies; elected to the National Academy of Engineering in 2026, for her outstanding contributions to engineering in biopharmaceutical development, analytical technologies, and manufacturing platforms for transformative therapies. Legal, Public Policy, and Regulatory experience gained through leadership of CMC regulatory functions as multiple global companies.

Ms. Shiv O'Neill serves as our Executive Vice President, General Counsel and Corporate Secretary, a position she has held since February 2024. Ms. O'Neill is responsible for the global strategy and operations of our legal team, including commercial, intellectual property, regulatory legal, labor & employment, M&A and business development legal, and the office of the corporate secretary. She also oversees Elanco's ethics and compliance and privacy matters. Before her current role, Ms. O'Neill served as Interim General Counsel and Corporate Secretary from November 2023 to February 2024, as Vice President, Deputy General Counsel - Americas from May 2022 to November 2023, and as Vice President, Deputy General Counsel - US from October 2021 to May 2022. Prior to joining Elanco, Ms. O'Neill served as Senior Counsel at Cummins Inc., a multinational corporation that designs, manufactures, and distributes engines, filtration and power generation products, from February 2016 to October 2021. Prior to joining Cummins, Ms. O'Neill was a Partner at Faegre Baker Daniels LLP (now Faegre Drinker Biddle & Reath LLP) from January 2010 to February 2016, and an Associate from March 2002 to December 2009. Ms. O'Neill started her career as in-house counsel at The Procter & Gamble Company. Ms. O'Neill received a Bachelor of Science from Loyola University Chicago and a Doctor of Jurisprudence degree from the Indiana University Maurer School of Law.

Mr. James M. Meer serves as our Senior Vice President, Chief Accounting Officer. Prior to joining Elanco in September 2018, Mr. Meer served as the Chief Financial Officer of Healthx, Inc., a healthcare technology company, which he joined in June 2017. He served as Senior Vice President of Finance at Appirio, an information technology consulting company, from 2014 to 2017 and as Vice President and Corporate Controller at Salesforce (previously ExactTarget), a cloud-based software company, from 2011 to 2014. Prior to 2011, Mr. Meer held various financial, accounting and strategy positions at 3M (previously Aearo Technologies), Hillrom, Hillenbrand Industries and Ernst & Young LLP. Mr. Meer received his bachelor's degree in accounting and business from Marian University and earned his Master of Business Administration from Xavier University.

Ms. Grace McArdle serves as our Executive Vice President, Manufacturing and Quality, a position she has held since July 2023. Prior to this position, Ms. McArdle held roles of increasing responsibility at Elanco, including among others, Vice President Supply Chain Operations from March 2020 to July 2023, Executive Director of Manufacturing Strategy and Operational Excellence from May 2019 to March 2020, Senior Director Operational Excellence from April 2018 to May 2019, and multiple leadership roles within internal and external manufacturing operations. Ms. McArdle held roles at both Lilly, both in the US and Ireland which she first joined in September 2000. Ms. McArdle holds two master's degrees in engineering - Biopharmaceutical Engineering from University College Dublin and Chemical Engineering from Queen's University Belfast.

Mr. Rajeev A. Modi serves as our Executive Vice President, U.S. Pet Health and Global Digital Transformation. At Elanco, he is poineering innovation and growth within U.S. Pet Health, overseeing approvals of three blockbuster-potential products: Canine Parvo Monoclonal Antibody, Zenrelia, and Credelio Quattr. Mr. Modi joined Elanco in this role in March of 2022, after serving as Vice President and General Manager of Enhancers and Components at Conagra Brands from May 2021 to April 2022. At Conagra Brands he was responsible for the company's substantial Grocery business, positioning it for profitable growth. Prior to that, he held numerous Vice President roles at J.M. Smuck

Mr. David S. Kinard serves as our Executive Vice President, Human Resources, Corporate Communications and Administration. Mr. Kinard brings valuable leadership experience within the pharmaceutical industry and years of managing human resources and communication programs to this position. He assumed his current role in August 2020 and has led our Human Resources function since our spin-off from Lilly in 2018. Mr. Kinard joined Lilly in 1997 and served in a wide variety of positions, including as Vice President of Human Resources of Lilly International and as a human resources leader in other Lilly businesses and functions. He holds a bachelor's degree in social science and broadcast communications and a master's degree in organizational behavior from Brigham Young University.

Mr. Jose Manuel Correia de Simas, PhD serves as our Executive Vice President, U.S. Farm Animal Business. Dr. Simas rejoined Elanco in this role in April 2020, after serving as President of Trouw Nutrition USA, an animal nutrition company, from 2018 to March 2020. In this role, he led its strategic change agenda to improve business quality and manufacturing productivity while building key capabilities in marketing, innovation, manufacturing and commercial excellence. Dr. Simas originally joined Elanco (then-owned by Lilly) in 2000 as product manager for our Rumensin product, and throughout his career has served in key roles in the U.S. and internationally, including senior director of Latin America and Global Aquaculture, senior director of our U.S. Beef business and area director for Central, Eastern Europe, North Africa and Middle East. He received a bachelor's degree from the Federal University of Lavras in Brazil and holds a master's degree and a doctorate in animal nutrition and physiology from the University of Arizona, as well as a post doctorate from the University of Sao Paulo, Brazil.